The Journal of Autism and Developmental Disorders have found that the mRNA level for cannabinoid receptor type 2 (CB2) was significantly increased in children with altered immune responses linked to autism. The mRNA level for cannabinoid receptor type 2 (CB2) was significantly increased in these children, which led them to conclude that “ data indicates CB2 receptor as a potential therapeutic target for the pharmacological management of the autism care.” View Source
In the United States, non-FDA approved CBD products are classified as Schedule I drugs under the Controlled Substances Act. This means that production, distribution, and possession of non-FDA approved CBD products is illegal under federal law. In addition, in 2016 the Drug Enforcement Administration added "marijuana extracts" to the list of Schedule I drugs, which it defined as "an extract containing one or more cannabinoids that has been derived from any plant of the genus Cannabis, other than the separated resin (whether crude or purified) obtained from the plant." Previously, CBD had simply been considered "marijuana", which is a Schedule I drug.